Viridian Therapeutics Stock Price Patterns
| VRDN Stock | USD 33.00 0.57 1.70% |
Momentum 60
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (1.06) | EPS Estimate Current Year (3.54) | EPS Estimate Next Year (3.57) | Wall Street Target Price 41.8824 | EPS Estimate Current Quarter (0.94) |
Using Viridian Therapeutics hype-based prediction, you can estimate the value of Viridian Therapeutics from the perspective of Viridian Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Viridian Therapeutics using Viridian Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Viridian using crowd psychology based on the activity and movement of Viridian Therapeutics' stock price.
Viridian Therapeutics Short Interest
An investor who is long Viridian Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Viridian Therapeutics and may potentially protect profits, hedge Viridian Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 21.1697 | Short Percent 0.0886 | Short Ratio 5.23 | Shares Short Prior Month 8.7 M | 50 Day MA 31.6774 |
Viridian Therapeutics Hype to Price Pattern
Investor biases related to Viridian Therapeutics' public news can be used to forecast risks associated with an investment in Viridian. The trend in average sentiment can be used to explain how an investor holding Viridian can time the market purely based on public headlines and social activities around Viridian Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Viridian Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Viridian Therapeutics.
Viridian Therapeutics Implied Volatility | 1.33 |
Viridian Therapeutics' implied volatility exposes the market's sentiment of Viridian Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viridian Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viridian Therapeutics stock will not fluctuate a lot when Viridian Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Viridian Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Viridian because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Viridian Therapeutics after-hype prediction price | USD 33.2 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Viridian contract
Based on the Rule 16, the options market is currently suggesting that Viridian Therapeutics will have an average daily up or down price movement of about 0.0831% per day over the life of the 2026-04-17 option contract. With Viridian Therapeutics trading at USD 33.0, that is roughly USD 0.0274 . If you think that the market is fully incorporating Viridian Therapeutics' daily price movement you should consider acquiring Viridian Therapeutics options at the current volatility level of 1.33%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Viridian Therapeutics Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Viridian Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Viridian Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Viridian Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Viridian Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Viridian Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Viridian Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Viridian Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Viridian Therapeutics' historical news coverage. Viridian Therapeutics' after-hype downside and upside margins for the prediction period are 30.49 and 35.91, respectively. We have considered Viridian Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Viridian Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Viridian Therapeutics is based on 3 months time horizon.
Viridian Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Viridian Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viridian Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Viridian Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.62 | 2.71 | 0.20 | 0.39 | 9 Events / Month | 7 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
33.00 | 33.20 | 0.61 |
|
Viridian Therapeutics Hype Timeline
Viridian Therapeutics is at this time traded for 33.00. The entity has historical hype elasticity of 0.2, and average elasticity to hype of competition of 0.39. Viridian is forecasted to increase in value after the next headline, with the price projected to jump to 33.2 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.61%, whereas the daily expected return is at this time at 0.62%. The volatility of related hype on Viridian Therapeutics is about 432.22%, with the expected price after the next announcement by competition of 33.39. The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (247.39 M). Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Viridian Therapeutics Basic Forecasting Models to cross-verify your projections.Viridian Therapeutics Related Hype Analysis
Having access to credible news sources related to Viridian Therapeutics' direct competition is more important than ever and may enhance your ability to predict Viridian Therapeutics' future price movements. Getting to know how Viridian Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Viridian Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| QURE | Uniqure NV | 0.87 | 11 per month | 0.00 | (0.13) | 9.37 | (10.75) | 60.67 | |
| GPCR | Structure Therapeutics American | 0.43 | 11 per month | 2.79 | 0.18 | 8.96 | (5.94) | 110.34 | |
| EWTX | Edgewise Therapeutics | (1.33) | 10 per month | 4.04 | 0.17 | 14.33 | (5.57) | 38.85 | |
| GLPG | Galapagos NV ADR | 0.82 | 3 per month | 1.31 | 0.03 | 2.62 | (2.52) | 7.08 | |
| OCUL | Ocular Therapeutix | 0.10 | 26 per month | 0.00 | (0.04) | 6.04 | (5.06) | 35.70 | |
| VERA | Vera Therapeutics | 0.96 | 10 per month | 3.00 | 0.15 | 10.77 | (4.62) | 23.44 | |
| RCUS | Arcus Biosciences | 4.19 | 10 per month | 4.05 | 0.09 | 6.88 | (6.53) | 21.81 | |
| CLDX | Celldex Therapeutics | 0.10 | 19 per month | 0.00 | (0.04) | 6.44 | (5.57) | 13.96 | |
| IBRX | Immunitybio | (0.19) | 6 per month | 4.26 | 0.19 | 11.16 | (7.49) | 51.87 | |
| COGT | Cogent Biosciences | 0.32 | 9 per month | 2.18 | 0.13 | 5.94 | (4.44) | 126.24 |
Viridian Therapeutics Additional Predictive Modules
Most predictive techniques to examine Viridian price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Viridian using various technical indicators. When you analyze Viridian charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Viridian Therapeutics Predictive Indicators
The successful prediction of Viridian Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Viridian Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Viridian Therapeutics based on analysis of Viridian Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Viridian Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Viridian Therapeutics's related companies. | 2025 | 2026 (projected) | Dividend Yield | 8.52E-4 | 0.001448 | Price To Sales Ratio | 3.9K | 4.1K |
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Viridian Stock
| 0.92 | APLT | Applied Therapeutics | PairCorr |
| 0.84 | LYRA | Lyra Therapeutics | PairCorr |
| 0.83 | EVGN | Evogene | PairCorr |
| 0.78 | MBIO | Mustang Bio | PairCorr |
| 0.78 | CRBP | Corbus Pharmaceuticals | PairCorr |
| 0.77 | SGMO | Sangamo Therapeutics | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Viridian Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could Viridian diversify its offerings? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viridian Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.03) | Revenue Per Share | Quarterly Revenue Growth 819.581 | Return On Assets | Return On Equity |
Understanding Viridian Therapeutics requires distinguishing between market price and book value, where the latter reflects Viridian's accounting equity. The concept of intrinsic value—what Viridian Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viridian Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viridian Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.